Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: The Motley Fool
Editas Expands Its Celgene Partnership After Another Strong Quarter Editas Medicine ( NASDAQ:EDIT GAAP Before we get there, let's have a look at how those headline numbers fared relative to the same year-ago period: Metric Q 09 Q 08 Growth Collaboration and other R&D revenue $.8 million $. million (7.%) GAAP net income (loss) ($.9 million) ($. million) N/A GAAP net income (loss) per share ($0.) ($0.) Data source: Editas Medicine. R&D = research and development. GAAP = generally accepted accounting principles. On core medicine portfolio advancements First, investors should note that Editas' revenue decline was almost entirely driven by $ million in revenue recognized in last year's third quarter Allergan Editas' R&D expenses grew 0.% year over year, to $.7 million, largely due to process and platform development costs incurred as part of a profit-sharing agreement with Allergan for EDIT-0. IMAGE SOURCE: GETTY IMAGES. To that end, the first potential patient for EDIT-0 has been successf
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.MarketBeat
- Editas Medicine to Participate in Upcoming Investor ConferencesGlobeNewswire
- Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]Yahoo! Finance
- Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]Yahoo! Finance
EDIT
Earnings
- 11/4/24 - Beat
EDIT
Sec Filings
- 11/12/24 - Form SC
- 11/4/24 - Form SC
- 11/4/24 - Form 10-Q
- EDIT's page on the SEC website